{
    "clinical_study": {
        "@rank": "80622", 
        "acronym": "DIGIT", 
        "arm_group": [
            {
                "arm_group_label": "Riociguat+Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo"
            }, 
            {
                "arm_group_label": "Placebo+Riociguat", 
                "arm_group_type": "Experimental", 
                "description": "Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold\n      causing acute lowering of blood flow through the digits. In this trial the safety and\n      efficacy as well as the effect of one dose of the sGC stimulator Riociguat on digital blood\n      flow will be measured during a cold exposure test in patients suffering from Raynaud's\n      phenomenon. Measurements of two periods will be compared: in one period the patient will be\n      given active drug and in the other period  a placebo."
        }, 
        "brief_title": "Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Raynaud Disease", 
        "condition_browse": {
            "mesh_term": "Raynaud Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients suffering from Raynaud's phenomenon diagnosed at least \u22651 year before\n             beginning of the study of the following origin:\n\n               -  idiopathic (primary)\n\n               -  limited cutaneous Scleroderma associated\n\n               -  diffuse cutaneous Scleroderma associated\n\n               -  mixed connective tissue disease associated\n\n        Exclusion Criteria:\n\n          -  Patients taking medication interfering with the digital flow measurement such as\n             calcium channel blockers (CCB), phosphodiesterase 5 (PDE5) inhibitors, endothelin\n             receptor antagonists (ERA), Nitrates\n\n          -  Smokers\n\n          -  Systolic blood pressure (SBP) below 105mmHg at rest"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926847", 
            "org_study_id": "16787", 
            "secondary_id": "2013-001899-38"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Riociguat+Placebo", 
                    "Placebo+Riociguat"
                ], 
                "intervention_name": "Riociguat (Adempas, BAY63-2521)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Riociguat+Placebo", 
                    "Placebo+Riociguat"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Digital ischemia", 
            "Raynaud's phenomenon"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "K\u00f6ln", 
                    "country": "Germany", 
                    "state": "Nordrhein-Westfalen", 
                    "zip": "50931"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "Pulse rate", 
                "safety_issue": "Yes", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "Incidence of participants showing changes during clinical laboratory and hematology assessment", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 5 weeks"
            }, 
            {
                "measure": "Plasma concentration at 2 h after riociguat administration", 
                "safety_issue": "No", 
                "time_frame": "After 2 hours"
            }, 
            {
                "measure": "Placebo corrected change in digital blood flow at room temperature, measured by Laser Doppler Perfusion Imaging", 
                "safety_issue": "No", 
                "time_frame": "At baseline and after 2h"
            }, 
            {
                "measure": "Placebo corrected change in digital blood flow during cold exposure, measured by Laser Doppler Perfusion Imaging", 
                "safety_issue": "No", 
                "time_frame": "At baseline and after 2h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}